Get Access Now: Car t Cell Therapy for Aggressive Non-Hodgkin Lymphoma

November 17, 2017 | City of Hope

City of Hope is now offering the first-ever FDA-approved CAR T cell therapy for adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.

Continue Reading

Stephen Forman, M.D., Inducted into AAP

May 30, 2018 | Michael Easterling

Stephen J. Forman, M.D., the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, has been inducted as a member of the Association of American Physicians.

Larry Kwak, M.D., Ph.D., Receives Grant for Promising Lymphoma Work

January 12, 2018 | Letisia Marquez

Larry Kwak, M.D., Ph.D., received a grant to support his work with mantle cell lymphoma from the Leukemia & Lymphoma Society, the world’s largest voluntary health organization dedicated to fighting blood cancer.

Geriatric assessment guides treatment strategy for older adults with cancer

December 1, 2017 | City of Hope

Researchers developed a self-administered geriatric assessment to identify areas of vulnerability and guide interventions for older adults with cancer.

Renowned Cancer Researcher Named President of City of Hope National Medical Center and Physician-in-Chief of City of Hope

November 28, 2017 | City of Hope

Michael A. Caligiuri, M.D., a world-renowned cancer researcher, has been named president of City of Hope National Medical Center and physician-in-chief of City of Hope.

City of Hope’s Ravi Salgia, M.D., Ph.D., honored by the IACA

June 2, 2017 | Letisia Marquez

City of Hope’s Ravi Salgia, M.D., Ph.D., whose accomplishments as a medical oncologist and researcher have helped shape modern cancer medicine, was celebrated at ASCO by the Indo-American Cancer Association (IACA) for his contributions to the field.

Translational researcher Larry Kwak explores lymphoma therapy's frontier

May 30, 2015 | City of Hope Staff

Lymphoma expert Larry Kwak has plans to improve the vaccine-based immunotherapy for which he is known. CAR T cells hold promise.